Is Apremilast (Otezla) in shortage in 2026? Get the latest update on availability, pricing, alternatives, and how to find it in stock near you.
If you've been struggling to get your hands on Apremilast (brand name Otezla), you're probably wondering: is there a shortage? The answer is more nuanced than a simple yes or no.
As of early 2026, Apremilast is not listed on the FDA's Drug Shortage Database. There is no official supply shortage of this medication. However, many patients are still experiencing significant difficulty filling their prescriptions — and the reasons have more to do with insurance, cost, and pharmacy access than with actual manufacturing or supply problems.
Let's break down what's really happening and what you can do about it.
No — not in the traditional sense. Unlike medications such as Adderall or certain GLP-1 drugs that have faced genuine supply shortages due to manufacturing constraints and surging demand, Apremilast's availability issues are primarily access-related.
The medication is being manufactured and distributed normally by Amgen. But patients face a different kind of scarcity:
These factors combine to create what feels like a shortage even when the supply itself is adequate.
There are several converging factors that make Apremilast difficult to access in 2026:
Apremilast is classified as a specialty medication, which means it's typically not available at your local pharmacy. Instead, it's dispensed through specialty pharmacies that ship directly to your home. While these pharmacies provide valuable support services, the process takes longer than a standard prescription fill.
For a deeper look at why Apremilast is so hard to find, see our detailed explainer.
Nearly every insurance plan requires prior authorization for Apremilast. Many plans also impose step therapy requirements, meaning you must try and fail on a cheaper medication (usually Methotrexate) before Apremilast is approved. Initial denials are common, and the appeals process can take weeks.
Despite FDA approval of generic apremilast applications, patent litigation has prevented any generic version from reaching the U.S. market. This situation is expected to continue until approximately 2028-2029. Without generic competition, there's no lower-cost alternative from a different manufacturer to increase overall supply availability.
The cost landscape for Apremilast in 2026:
For a complete breakdown of ways to save money on Apremilast, including copay cards, patient assistance, and discount programs, see our dedicated guide.
While Apremilast itself hasn't changed much, the treatment landscape has evolved:
Amgen launched Otezla XR, a 75 mg extended-release formulation that's taken once daily instead of twice daily. This is the same active ingredient (Apremilast) in a more convenient dosing schedule. It doesn't require the 5-day titration that standard Otezla does. If you're already on Otezla, ask your doctor about switching to the XR version for simplicity.
The landscape of oral treatments for psoriasis continues to expand. Deucravacitinib (Sotyktu), a TYK2 inhibitor approved in 2022, is now more widely available and gives patients another oral option. If Apremilast access is a persistent problem, explore our guide to alternatives to Apremilast.
If you need Apremilast now, here are your best steps:
Start at Medfinder to find pharmacies with Apremilast in stock near you. This saves time versus calling pharmacies individually.
Amgen's support program can help with:
Call 1-833-44AMGEN (1-833-442-6436).
Give yourself at least 7-10 days of lead time on refills. Specialty pharmacy processing and shipping takes longer than a retail pharmacy pickup. If your insurance requires annual PA renewals, start the process a month early.
If your insurance denies coverage, you have the right to appeal. Ask your doctor to provide:
Many denials are overturned on appeal — don't accept the first "no" as final.
Apremilast isn't in a traditional supply shortage in 2026, but the access challenges are very real. Between specialty pharmacy requirements, insurance barriers, and costs that can exceed $6,000 per month without coverage, getting this medication takes more effort than it should.
The good news: with planning, the right support programs, and tools like Medfinder, most patients can get the Apremilast they need. Start early, use every resource available to you, and don't hesitate to push back on insurance denials.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
